Sano Chemicals, Inc. — Department of Health and Human Services STTR Phase I: NIAID

Sano Chemicals, Inc. — STTR Phase I award from Department of Health and Human Services.

Amount
$529,551
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
STTR · Phase I
Topic
NIAID
Solicitation
PA15-270
NAICS
Place of performance
TX
Period
2016-03-15 → 2018-06-30

Description

DESCRIPTION provided by applicant Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have also revealed that occidiofungin has a novel mechanism of action Occidiofungin is a potent antifungal against fluconazole and caspofungin resistant Candida albicans Occidiofungin triggers cell death by inducing apoptosis in yeast cells Occidiofungin has minimal toxicity in mice at doses exceeding mg kg Furthermore occidiofungin was shown to reduce Candida glabrata load in the kidneys of infected mice All these studies point to the need to further the preclinical development of this novel compound The major impediment to furthering investigational studies on this unique antifungal compound is the poor yield from culture liquor The goal of this application is to enhance the yield and purity of occidiofungin following fermentation Three approaches will be explored to increase the yield of the antifungal compound First media components will be screened to determine their effect on the production levels of the antifungal compound Second a molecular based approach will be used to determine whether an increase in production of occidiofungin is possible through genetic manipulation of B contaminans Our third approach is to develop a heterologous expression system The last component of the application is to determine the most effective means of extracting and purifying the antifungal compound from the fermentation liquor These studies will enable exploratory structure activity relationship SAR studies on occidiofungin This work is necessary for furthering additional studies aimed at developing the antifungal compound as a new therapeutic PUBLIC HEALTH RELEVANCE The proposal addresses the need for the development of a novel broad spectrum antifungal for the treatment of systemic fungal infections We will investigate means of enhancing the production and purification of an antifungal compound named occidiofungin This work is necessary for promoting the production of sufficient amounts of occidiofungin for the completion of the required preclinical studies that are needed for filing n Investigational New Drug IND application